FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market

RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”